BioSpace News Archive

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the final data assessment from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 CF patients with at least one nonsense mutation. In the final assessment, ELX-02 demonstrated clinically relevant improvement in ppFEV1.

Pharma-Bio Serv, Inc. announced that revenues for the three and six months ended April 30, 2023 were approximately $4.6 and $8.8 million, respectively, a decrease of approximately $0.4 and $1.2 million, respectively, when compared to the same periods last year.

GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a study in Frontiers in Microbiomes.